Posted on 25th November 2014
Popular in the US, Avastin is used for patients with age-related macular degeneration (AMD). It has been on the market for years, gone through all the testing and has been proven to be as effective as Lucentis, the NHS approved drug for the same condition. The difference is cost. Lucentis typically costs around £700 per treatment, compared to Avastin which is about £70. Yet red tape seems to be halting its use.
It is currently unlicensed in the UK so should anything go wrong with its use, the practitioner may not be legally covered. However, in times of austerity and it is perhaps time for the NHS to move forward and license its use.
12th August 2019
Cameron Optometry is an award-winning optometry practice and eyewear boutique, based in Edinburgh’s New Town. The practice is now looking to welcome a new member to our friendly team. The role is hu...Read more
01st August 2019
Encouraging news for the battle against increasing rates of short-sightedness in children Cameron Optometry is delighted to announce it now has over 50 patients using Myopia Management contact lense...Read more